Patient Advocacy Groups Challenge 340B Drug Pricing Program's Current Implementation

Patient advocacy organizations ADAP Advocacy and CF United have taken a significant step in highlighting systemic issues within the 340B Drug Pricing Program by filing joint amicus curiae briefs supporting a legal challenge against the Health Resources Services Administration.

The briefs argue that the program has dramatically expanded without corresponding increases in meaningful patient support. At the core of their argument is the assertion that many large hospital systems and service providers are exploiting the program for financial gain, while patients continue to struggle with substantial medical debt.

According to Brandon M. Macsata, CEO of ADAP Advocacy, the 340B Program has become a 'cash cow' for covered entities, with mounting evidence suggesting that patient benefits have not kept pace with program growth. Current estimates indicate that individuals in the United States collectively owe approximately $220 billion in medical debt.

William Sarraille, the organization's Special Counsel for 340B Issues, emphasized the need to refocus the program on patient needs. He suggested that the rebate model could serve as a mechanism to ensure patients understand and potentially benefit from the pricing structures that generate billions in revenue for healthcare providers.

Guy Anthony, Chair of ADAP Advocacy's 340B Patient Advisory Committee, highlighted the program's particular importance for people living with HIV. He stressed that healthcare equity depends on meaningful reform that prioritizes patient outcomes over institutional profits.

The legal filing represents a critical intervention in ongoing debates about healthcare pricing and access, challenging healthcare systems to demonstrate more direct patient benefits from drug pricing programs. By drawing attention to the disconnect between program expansion and patient support, ADAP Advocacy and CF United are pushing for a more transparent and patient-centered approach to drug pricing.